资源 » 参考数据库 » 客户发表文献

至今，GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次，处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果，再次证明GenScript 有能力帮助业内科学家Make research easy.

Strength and medium-term impact of HisAK70 immunization in dogs: Vaccine safety and biomarkers of effectiveness for ex vivo Leishmania infantum infection.

Comp Immunol Microbiol Infect Dis. 2019;

Martínez-Rodrigo A, Mas A, Fernández-Cotrina J, Belinchón-Lorenzo S, Orden JA, Arias P, de la Fuente R, Carrión J, Domínguez-Bernal G.

Products/Services Used	Details	Operation
Peptide Synthesis	… CAA59793.1, -70-). The amino acid sequences of the peptides used are shown in Table 1. These peptides and the Hsp70 protein were purchased from GenScript (Piscataway, NJ, USA). The vaccination schedule consisted …	Get A Quote

摘要

HisAK70 candidates have successfully been tested in cutaneous (CL) and visceral leishmaniosis (VL) mouse models. Here, we analyse different biomarkers in dog trials after a heterologous immunization strategy with a HisAK70 candidate (plasmid DNA plus adoptive transfer of peripheral blood-derived dendritic cells (DCs) pulsed with the same pathoantigen and CpG ODN as an adjuvant) to explore the antileishmanial activity in an ex vivo canine co-culture system in the presence of Leishmania infantum parasites. In the canine model, the heterologous HisAK70 vaccine could decrease the infection index in the DC-T cell co-culture system by up to 54% after 30 days and reach almost 67% after 100 days post-immunization, resp... More